nrx194204
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00630760)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CC(/C=C/[C@@H]1C[C@]1(C)c1ccc2c(c1)C(C)(C)CCC2(C)C)=C\C(=O)O- Mol. weight
- 352.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL75133 ↗
Also known as
- agn194204
- agn 194204
- agn-194204
- agn-194204
- agn-194204
- irx4204
- irx4204
- irx-4204
- irx-4204
- kb-145960
- kb-145960
- nrx194204
- nrx194204
- nrx 194204
- nrx 194204
- nrx 194204
- nrx-194204
- nrx-194204
- nrx-194204
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02991651 | Phase 1 | May 1, 2016 | Dartmouth University, Io Therapeutics |
| NCT02438215 | Phase 1 | Aug 1, 2014 | Io Therapeutics, Molecular NeuroImaging |
| NCT01540071 | Phase 2 | Aug 1, 2011 | Hoag Memorial Hospital Presbyterian, Io Therapeutics |
| NCT00964132 | Phase 2 | Mar 1, 2009 | NuRx Pharmaceuticals, Inc. |
| NCT00630760 | Phase 1 | Feb 1, 2008 | University of Southern California |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Io Therapeutics | For profit | 3 | 3 | 2 | 2011 |
| Dartmouth University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Hoag Memorial Hospital Presbyterian | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Molecular NeuroImaging | For profit | 1 | 0 | 1 | 2014 |
| NuRx Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2009 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2008 |
6 organizations
Page 1 / 1